Beyond Achondroplasia

Growing together with Clara

January 5, 2017
by inesp.alves
5 Comments

Therachon protein for achondroplasia: TA-46

A press release from Business Wire stated that Therachon AG, a biotechnology company focused on rare genetic diseases, announced today it has appointed Luca Santarelli, M.D., as Chief Executive Officer and Director, and raised more $5 million for new medicines R&D (research a … Continue reading

October 1, 2015
by inesp.alves
2 Comments

Soluble FGFR3 going forward with Therachon

Soluble FGFR3 was first mentioned here in September 2013. This protein is able to restore growth by acting has a decoy receptor and prevents FGFs from binding to mutant FGFR3 and was able to increase bone length and reduce complications associated with achondroplasia in transgenic … Continue reading

September 18, 2014
by inesp.alves
5 Comments

Statins for achondroplasia?

Nature journal published yesterday an article connecting statins to achondroplasia treatment. You can read the abstract of the article “Statin treatment rescues FGFR3 skeletal dysplasia phenotypes“.A. Yamashita et al. Nature,doi:10.1038/nature13775, 2014 Statins or HMG-CoA reductase inhibitors are a class of drugs used … Continue reading

September 5, 2014
by inesp.alves
5 Comments

5th International Congress around achondroplasia and other skeletal dysplasias

Alpe Foundation, one of the most important spanish and european organisations for achondroplasia, is promoting  the 5th Congress, that will take place in north of Spain, Gijon, on the 11th, 12th and 13th October 2014. Their webpage is in spanish … Continue reading

Translate »